CAS 866460-33-5

Setipiprant

Description:

Setipiprant is a chemical compound primarily known for its role as a selective antagonist of the prostaglandin D2 receptor 2 (DP2), which is implicated in various allergic and inflammatory conditions. It is classified as a small molecule and has been investigated for its potential therapeutic applications in treating conditions such as asthma and allergic rhinitis. The molecular structure of Setipiprant includes a core that allows for specific binding to the DP2 receptor, thereby inhibiting its activity. This action can lead to a reduction in inflammation and other symptoms associated with allergic responses. Setipiprant is typically administered in oral form and has undergone various clinical trials to assess its efficacy and safety profile. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are important for understanding its therapeutic potential and dosing regimens. Overall, Setipiprant represents a promising avenue in the development of targeted therapies for allergic diseases.

Formula: C₂₄H₁₉FN₂O₃

InChI: InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)

InChI key: InChIKey=IHAXLPDVOWLUOS-UHFFFAOYSA-N

SMILES: C(C(O)=O)N1C2=C(C=3C1=CC=C(F)C3)CN(C(=O)C=4C5=C(C=CC4)C=CC=C5)CC2

Synonyms:

• ACT 129968
• 2-(2-(1-Naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
• Setipiprant
• 8-Fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5H-pyrido[4,3-b]indole-5-acetic acid
• 5H-Pyrido[4,3-b]indole-5-acetic acid, 8-fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-
• setipplant
• 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid(Setipiprant,ACT129968)
• Setipiprant(ACT-129968, KYTH-105)
• 2-(2-(1-phthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
• ACT129968;ACT-129968;ACT 129968
• 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid
• CS-2052
• Setipiprant(ACT-129968)
• RU58841 // Minoxidil // Setipiprant
• ACT 129968; ACT129968; KYTH-105; KYTH105; KYTH 105; SETIPIPRANT
• Seripiprant
• 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
• ACT129968
• CS-2512
• Setipirant

2-(2-(1-Naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid

CAS: 866460-33-5

Formula: C₂₄H₁₉FN₂O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 402.4177

Ref: IN-DA00GU6H

Setipiprant

CAS: 866460-33-5

Setipiprant

Purity: ≥98%

Molecular weight: 402.42g/mol

Ref: 54-BUP11176

Setipiprant

CAS: 866460-33-5

Setipiprant (ACT-129968) is an oral CRTH2 antagonist for asthma/allergy, targeting PGD2-induced inflammation (IC50: 6.0 nM).

Formula: C₂₄H₁₉FN₂O₃

Purity: 99.16%

Color and Shape: Solid

Molecular weight: 402.42

Ref: TM-T3520

Setipiprant(ACT-129968)

CAS: 866460-33-5

Setipiprant is a CRTH2-selective antagonist, which has been shown to be effective in reducing the incidence of asthma exacerbations and bronchoconstriction. It also has a good safety profile with no significant adverse effects observed in clinical studies. Setipiprant binds to the CRTH2 receptor and blocks its activation by prostaglandin D2 (PGD2) or leukotriene B4 (LTB4). This inhibition prevents the release of inflammatory mediators from mast cells, which are responsible for airway inflammation in asthma. Setipiprant is being developed as a potential treatment for chronic asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). The molecule has been shown to bind to the CRTH2 receptor with an affinity that is about 10 times higher than that of cetirizine, another anti-inflammatory drug. This binding profile makes setipiprant an ideal candidate for treatment of inflammatory diseases

Formula: C₂₄H₁₉FN₂O₃

Purity: Min. 95%

Molecular weight: 402.42 g/mol

Ref: 3D-RJB46033